ESMO 2025 | Three vs six cycles of platinum-based chemotherapy for aUC in the DISCUS trial
Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, comments on the Phase II DISCUS trial (NCT06892860), which compared three versus six cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial carcinoma (aUC). Findings demonstrated comparable overall and progression-free survival between the two regimens, alongside improved quality of life and a reduction in severe adverse events with the shorter chemotherapy course. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, Dr Grande presented the results yesterday from the DISCUS trial, and patients received three versus six cycles of platinum-based chemotherapy followed by the atezolizumab maintenance phase if they achieved clinical benefit to the chemotherapy regimen. And their main primary endpoint was the change in quality of life from baseline to the completion of cycle six and this endpoint favored the three cycle arm while they also showed overall survival, another primary endpoint of the trial, but the data is still immature so we need to see how this translates into the long term but for now there was no difference between the two arms and same applied for the progression-free survival which was one of the secondary endpoints
This transcript is AI-generated...
Yeah, Dr Grande presented the results yesterday from the DISCUS trial, and patients received three versus six cycles of platinum-based chemotherapy followed by the atezolizumab maintenance phase if they achieved clinical benefit to the chemotherapy regimen. And their main primary endpoint was the change in quality of life from baseline to the completion of cycle six and this endpoint favored the three cycle arm while they also showed overall survival, another primary endpoint of the trial, but the data is still immature so we need to see how this translates into the long term but for now there was no difference between the two arms and same applied for the progression-free survival which was one of the secondary endpoints
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
